Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
CLRB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.94%88.651.3%$803.98m
AMGNAmgen Inc.
-0.76%185.501.2%$628.99m
GILDGilead Sciences, Inc.
-2.14%65.550.9%$482.29m
BIIBBiogen Inc.
-4.17%321.171.3%$427.44m
ILMNIllumina, Inc.
-1.77%296.883.5%$311.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%418.622.6%$290.18m
VRTXVertex Pharmaceuticals Incorporated
-2.55%183.061.9%$253.58m
ALXNAlexion Pharmaceuticals, Inc.
-1.76%127.552.0%$219.68m
SRPTSarepta Therapeutics, Inc.
-2.87%136.5415.4%$152.33m
AAgilent Technologies, Inc.
-0.83%77.911.6%$150.84m
EXASExact Sciences Corporation
-0.42%83.2825.3%$132.28m
INCYIncyte Corporation
-0.49%83.332.5%$111.93m
ARRYArray BioPharma Inc.
-1.99%22.718.2%$108.01m
EXELExelixis, Inc.
-0.09%21.226.4%$82.07m
NBIXNeurocrine Biosciences, Inc.
-2.58%77.315.1%$77.22m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.